Beam Therapeutics Reports Positive Clinical Data for AATD Treatment; Plans Pivotal Trials

关键事实

1BEAM-302 at a 60 mg dose showed mean steady-state total AAT levels of 16.1 µM.

2All patients remained consistently above the 11 µM protective threshold with up to 12 months of follow-up.

3The company plans to advance the program to pivotal development based on the compelling data.

Beam Therapeutics announced updated Phase 1/2 clinical data for its base-editing candidate, BEAM-302, targeting Alpha-1 Antitrypsin Deficiency (AATD). The study revealed that a 60 mg dose achieved mean steady-state total AAT levels of 16.1 µM. Crucially, all participating patients remained consistently above the 11 µM protective threshold throughout a follow-up period of up to 12 months. These results demonstrate the treatment's potential to provide long-term therapeutic benefits through precise gene editing. Following these compelling results, the company plans to advance the BEAM-302 program into pivotal development stages. This transition marks a significant milestone in the regulatory pathway and significantly de-risks the company's clinical pipeline.

免费注册以访问此内容

创建免费账户